 |
|
|
| |
Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results
|
| |
| |
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
Aimee Wilkin1, Karen Tashima, Christine Katlama, Laura Waters, John Jezorwski, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh⁷, on behalf of the EMERALD and AMBER study groups
1Wake Forest School of Medicine, Winston-Salem, NC, USA; The Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA; HIV Clinical Research Unit, Hopital Pitie-Salpetriere, Paris, France; University College London Hospital, London, UK; Janssen Research & Development, Pennington, NJ, USA; Janssen Pharmaceutica NV, Beerse, Belgium; ⁷Janssen Research & Development LLC, Raritan, NJ, USA
|
| |
|
|
|
|
|
